Principal Financial Group Inc. Sells 25,200 Shares of Cellectis S.A. (NASDAQ:CLLS)

Principal Financial Group Inc. reduced its stake in Cellectis S.A. (NASDAQ:CLLS) by 5.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 411,800 shares of the biotechnology company’s stock after selling 25,200 shares during the period. Principal Financial Group Inc.’s holdings in Cellectis were worth $881,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Long Focus Capital Management LLC increased its holdings in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares during the last quarter. First Affirmative Financial Network bought a new stake in Cellectis in the 3rd quarter worth approximately $45,000. Finally, XTX Topco Ltd purchased a new stake in shares of Cellectis during the 2nd quarter worth approximately $29,000. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Barclays reduced their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. StockNews.com initiated coverage on shares of Cellectis in a report on Tuesday, December 31st. They issued a “sell” rating on the stock.

Cellectis Trading Down 7.5 %

CLLS stock opened at $1.68 on Friday. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis S.A. has a twelve month low of $1.41 and a twelve month high of $3.38. The stock has a market capitalization of $93.10 million, a price-to-earnings ratio of -1.29 and a beta of 3.08. The firm’s fifty day simple moving average is $1.84 and its two-hundred day simple moving average is $2.01.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The business had revenue of $18.05 million during the quarter, compared to analysts’ expectations of $5.00 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. As a group, analysts anticipate that Cellectis S.A. will post -0.46 earnings per share for the current year.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.